Earnings Alerts

Persistent Systems (PSYS) Earnings: 2Q Net Income Surges 24% to 3.25 Billion Rupees

By October 22, 2024 No Comments
  • Persistent Systems reported a net income of 3.25 billion rupees for the second quarter of 2024, marking a 24% increase year over year.
  • The company achieved a revenue of 29 billion rupees, which is a 20% increase from last year, surpassing the estimated 28.66 billion rupees.
  • Total costs for the company rose by 20% year over year, totaling 25.1 billion rupees.
  • Other income experienced a 25% increase, reaching 465.2 million rupees.
  • In terms of investment recommendations, there are 16 buy ratings, 9 hold ratings, and 11 sell ratings for the company.

A look at Persistent Systems Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth4
Resilience5
Momentum4
OVERALL SMART SCORE3.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking ahead, Persistent Systems Limited shows a promising long-term outlook based on the Smartkarma Smart Scores assessment. With a strong score in Resilience and Growth, the company demonstrates a solid foundation and potential for expansion. Persistent Systems, known for its outsourced software product development services, has garnered a respectable score for Dividend as well, indicating a commitment to rewarding its investors.

Additionally, the company’s momentum score reflects positive market sentiment and performance. While there is room for improvement in the Value aspect, the overall outlook for Persistent Systems appears favorable, backed by its robust scores across various key factors. With a track record of providing quality services in testing, support, and professional services, Persistent Systems seems well-positioned for sustained success in the long run.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars